Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Pharmacokinetics | Letter

Vancomycin pharmacokinetics in critically ill obese patients: can the clinician sit back and relax?

Authors: Patrick M. Honore, David De Bels, Luc Kugener, Sebastien Redant, Rachid Attou, Andrea Gallerani, Herbert D. Spapen

Published in: Critical Care | Issue 1/2019

Login to get access

Excerpt

The recently published study by Lin et al. provides valid pharmacokinetic (PK) data regarding continuous infusion of vancomycin (CIV) in obese versus non-obese patients. An important finding is that CIV in obese patients, whether or not receiving renal replacement therapy, consistently produced target “therapeutic” serum concentrations and resulted in a lower weight-based daily vancomycin exposure as compared to non-obese subjects [1]. …
Literature
1.
Lin H, Yeh DD, Levine AR. Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients. Crit Care. 2016;20(1):205.CrossRef
2.
Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–42.CrossRef
3.
van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.CrossRef
4.
Paiva RM, Mombach Pinheiro Machado AB, Zavascki AP, Barth AL. Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. J Clin Microbiol. 2010;48(12):4652–4.CrossRef
5.
Cristallini S, Hites M, Kabtouri H, Roberts JA, Beumier M, Cotton F, et al. New regimen for continuous infusion of vancomycin in critically ill patients. Antimicrob Agents Chemother. 2016;60(8):4750–6.CrossRef
Metadata
Title
Vancomycin pharmacokinetics in critically ill obese patients: can the clinician sit back and relax?
Authors
Patrick M. Honore
David De Bels
Luc Kugener
Sebastien Redant
Rachid Attou
Andrea Gallerani
Herbert D. Spapen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2311-2

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue

Letter

Feedback function for capillary refilling time measurement device

Research

Prevalence of post-traumatic stress disorder symptoms in adult critical care survivors: a systematic review and meta-analysis

Research

Albumin infusion rate and plasma volume expansion: a randomized clinical trial in postoperative patients after major surgery

Letter

Global warming “heating up” the ICU through Candida auris infections: the climate changes theory

Letter

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights

Research

The association between nutritional adequacy and 28-day mortality in the critically ill is not modified by their baseline nutritional status and disease severity